In a phase I trial of 14 patients with advanced ovarian cancer, the glutaminase-1 inhibitor IACS-6274—combined with bevacizumab and paclitaxel—showed safety and produced confirmed partial tumor responses in 9 of 13 evaluable participants. The regimen’s early efficacy signal is notable because it pairs metabolic targeting (glutaminase inhibition) with established ovarian cancer backbone therapies, potentially aiming to deepen and prolong responses. The trial remains small, but confirmed partial responses in the first-in-human setting support continued development and escalation plans. For biotech stakeholders, the key near-term impact will be whether response durability, biomarker-defined activity, and tolerability hold up as cohorts expand.
Get the Daily Brief